Vistagen initiated with a Buy at Stifel

Stifel initiated coverage of Vistagen with a Buy rating and $12 price target. Vistagen is an “undervalued late stage CNC play” with two shots at Phase 3 success in social anxiety, according to the analyst, who sees a “highly upside-biased” risk/reward into the fasedienol PALISADE-3/4 studies that are reading out in 2025.